Skip to Main

2022 Article Archive

More than two decades of UTSW research paves way for first-in-kind drug


A first-in-kind immune-modulating drug that arose from decades of basic research at UT Southwestern Medical Center has received approval from the U.S. Food and Drug Administration as a new treatment for myasthenia gravis.

Clinical trial shows stereotactic radiation extends systemic therapy and slows kidney cancer progression


A new study by the Kidney Cancer Program (KCP) at UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center shows that highly focused radiation to isolated metastases that progress despite drug therapy can prolong drug use in kidney cancer patients, saving the few other drugs for treating kidney cancer for future use.